elebsiran Updated Nov 6
The pivotal Phase 3 ECLIPSE 1 topline results for elebsiran plus tobevibart in chronic hepatitis delta will be presented as a late-breaking oral at AASLD on November 8, 2026, with an investor call on November 9. Positive data would support regulatory filings and validate the combination against bulevirtide; negative or mixed results would severely damage the company's lead program thesis. The stock surged ~11% on November 6 ahead of the readout, reflecting anticipation.
- Elebsiran plus tobevibart has FDA Breakthrough Therapy Designation and EMA PRIME Designation for chronic hepatitis delta, enabling expedited regulatory review.
- Phase 2 SOLSTICE data showed high rates of undetectable HDV RNA and ALT normalization, with durable 96-week suppression published in NEJM.
- The Norgine licensing deal (up to ~$645M) validates the program and provides a commercial partner for Europe, Australia and New Zealand.
- Bulevirtide (Hepcludex) was FDA-approved in May 2026 for chronic hepatitis delta, establishing a competitive benchmark that elebsiran/tobevibart must beat or match.
- The Phase 3 ECLIPSE 1 trial is open-label (not blinded), which can introduce bias and may limit the strength of the evidence for regulators.
- Multiple institutional investors trimmed or exited positions in Q2 2026, including Citadel (-52.8%), Millennium (-90.2%), and Jacobs Levy (-90.5%), signaling skepticism.